Alumis

Recent news

• Rating change
  Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)
  TipRanks · 2026/8/14
• Rating change
  Analysts' Top Healthcare Picks: UniQure (QURE), Alumis Inc. (ALMS)
  TipRanks · 2026/9/3
• Raymond James Maintains Alumis(ALMS.US) With Buy Rating
  Market Newswire · 2026/9/3
• Rating change
  Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)
  TipRanks · 2026/9/3
• Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
  TipRanks · 2026/9/10
• H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $15
  Market Newswire · 2026/10/5
• Rating change
  Morgan Stanley Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $39
  Market Newswire · 2026/8/17
• Rating change
  Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
  TipRanks · 2026/9/2
• Rating change
  Analysts' Opinions Are Mixed on These Healthcare Stocks: ProKidney (PROK), Crinetics Pharmaceuticals (CRNX) and Alumis Inc. (ALMS)
  TipRanks · 2026/8/11
• Rating change
  Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Satellos Bioscience (MSLE) and Alumis Inc. (ALMS)
  TipRanks · 2026/8/14
• Rating change
  A Quick Look at Today's Ratings for Alumis(ALMS.US), With a Forecast Between $15 to $37
  Market Newswire · 2026/9/3
• Rating change
  Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)
  TipRanks · 2026/8/14
• Rating change
  Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55
  Market Newswire · 2026/7/16
• Rating change
  Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
  TipRanks · 2026/7/16
• Alumis(ALMS.US) Director Buys US$10.73 Million in Common Stock
  Market Newswire · 2026/9/10
• Company notice
  Meiho Facility Works Ltd: It was selected as the commissioned contract reservation enterprise in the public offering proposal of "entrusting the construction consulting business of the alms-giving branch".
  JPX · 2022/8/18
• Rating change
  Stifel Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $44
  Market Newswire · 2026/8/14
• Rating change
  Guggenheim Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $34
  Market Newswire · 2026/8/14
• Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25
  Market Newswire · 2026/9/10
• Rating change
  Alumis Inc. (ALMS) Receives a Rating Update From a Top Analyst
  TipRanks · 2026/8/13

Headlines are aggregated automatically and are not independently verified or edited by our team.